Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec:66:217-226.
doi: 10.1016/j.breast.2022.10.016. Epub 2022 Oct 26.

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer

Elie Rassy  1 , Layal Rached  1 , Barbara Pistilli  2
Affiliations
Review

Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer

Elie Rassy et al. Breast. 2022 Dec.

Abstract

The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer has propelled the development of HER-targeting monoclonal antibodies (mAb) such as trastuzumab and pertuzumab, which led to dramatic improvements in survival outcomes. Lately, the great strides made toward developing antibody-conjugation methods have led to the development of a new class of compelling compounds, the antibody-drug conjugates (ADCs) targeting HER2 which have profoundly transformed the treatment landscape of breast cancer. HER2-targeting ADCs, trastuzumab-emtansine and trastuzumab-deruxtecan, have improved the overall survival in the second and third-line settings with manageable adverse events. Other HER2-targeting ADCs using novel technological advances in the antibody, linker and/or payload conception have shown promising activity in preclinical and clinical studies and some of them are now being evaluated in larger clinical trials. Multiple challenges still impede the success of ADCs in breast cancer namely the lack of a comprehensive understanding of resistance mechanisms as well as the mechanisms of action of ADCs in special subgroups of patients such as those with low or ultra-low HER2 expression and patients with brain or leptomeningeal metastases (BM). In this framework, we review the approved indications and ongoing trials for HER2-targeting ADCs, across patient subgroups, including those with BM and discuss the associated potential mechanisms of action and resistance. Last, we provide an overview of the future perspectives involving HER2-targeting ADCs in breast cancer.

Keywords: Antibody-drug conjugate; Breast cancer; HER2.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The other authors did not declare any conflict of interest.

Figures

Fig. 1
Fig. 1
Mechanisms of action of HER2-targeting ADC.
Fig. 2
Fig. 2
Mechanisms of resistance of HER2-targeted antibody-drug conjugates.
See this image and copyright information in PMC

References

    1. Wolff A.C., Hammond M.E.H., Allison K.H., et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Orthod. 2018;36:2105–2122. - PubMed
    1. Ravdin P.M., Chamness G.C. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-A review. Gene. 1995;159:19–27. - PubMed
    1. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–6487. - PMC - PubMed
    1. Klapper L.N., Waterman H., Sela M., et al. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 2000;60:3384–3388. - PubMed
    1. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. - PubMed

MeSH terms